Novo and Sanofi have backed a series A round for Inozyme Pharma, which is developing treatments for rare diseases affecting infants.
Inozyme Pharma, a US-based developer of medicines for rare infant diseases, closed a $49m series A round on Wednesday featuring pharmaceutical companies Novo and Sanofi.
Longitude Capital led the round, which also featured fellow venture capital firm New Enterprise Associates. The corporates invested through their respective corporate venturing subsidiaries, Novo Ventures and Sanofi Ventures.
Founded in 2016, Inozyme is using technology licensed from Yale University to develop enzyme replacement therapies to treat rare diseases in infants that involve the over-calcification…
